Streetbeat News

Regulatory

BA

Boeing's VP of Commercial Marketing, Hulst, announced that the company is adding an extra layer of oversight to the 737-9 door plug. This move is likely in response to safety and quality control measures.

Portfolio Pulse from Benzinga Newsdesk

January 29, 2024 | 2:04 pm

GOVX

GeoVax Labs, Inc. has announced a 1-for-15 reverse stock split in an effort to regain compliance with the Nasdaq's minimum bid price requirement. This corporate action is intended to boost the company's stock price above the Nasdaq's minimum threshold and avoid delisting.

Portfolio Pulse from Benzinga Newsdesk

January 29, 2024 | 2:01 pm

EIS

Reuters reports, citing the Gaza Health Ministry, that Israeli strikes on Gaza since October have resulted in 26,637 Palestinian deaths and 65,387 injuries.

Portfolio Pulse from Benzinga Newsdesk

January 29, 2024 | 1:55 pm

MMAT

Trading for MMAT was halted and then resumed at 8:55 AM ET, with updated quotation resumption times following the release of news.

Portfolio Pulse from Benzinga Newsdesk

January 29, 2024 | 1:55 pm

AMZN

IRBT

Amazon (AMZN) and iRobot (IRBT) have mutually agreed to terminate their acquisition deal due to the inability to secure approval from European Union regulators. The decision indicates that both companies see no clear path forward to satisfy the regulatory concerns that have been raised.

Portfolio Pulse from Benzinga Newsdesk

January 29, 2024 | 1:34 pm

AMZN

IRBT

iRobot has announced an operational restructuring plan after Amazon and iRobot mutually decided to terminate their merger agreement. The termination follows regulatory concerns that may have impeded the completion of the merger.

Portfolio Pulse from Benzinga Newsdesk

January 29, 2024 | 1:32 pm

KAVL

Kaival Brands' partner Bidi Vapor is challenging the FDA's denial of its Premarket Tobacco Product Application (PMTA) for its 'Classic' tobacco-flavored electronic nicotine delivery systems (ENDS). The FDA's decision is a significant setback for Bidi Vapor, as the 'Classic' flavor is a key product in its lineup. Bidi Vapor believes that the FDA's decision is not in line with the public health objectives and is contesting the denial to potentially reverse the decision.

Portfolio Pulse from Benzinga Newsdesk

January 29, 2024 | 1:18 pm

ARQT

Arcutis Biotherapeutics announced that the Journal of American Academy of Dermatology has published results from its Phase 3 STRATUM trial for ZORYVE Foam, 0.3%. The trial results indicate that the novel steroid-free topical foam is effective in controlling seborrheic dermatitis. ZORYVE has been approved for the treatment of seborrheic dermatitis in individuals aged 9 years and older.

Portfolio Pulse from Benzinga Newsdesk

January 29, 2024 | 1:15 pm

QMCO

Quantum Corp. announced that its plan to regain compliance, submitted on January 16, 2024, has been approved by Nasdaq. This approval is a positive step for the company in maintaining its listing on the stock exchange.

Portfolio Pulse from Benzinga Newsdesk

January 29, 2024 | 1:11 pm

LGVN

Longeveron has received a notice of allowance for a United States patent for its Medicinal Signaling Cells (MSC) technology. This patent allowance is a significant step in protecting the company's intellectual property and may enhance its competitive position in the regenerative medicine market. The patent covers the methods of preparing and using MSCs, which are a cornerstone of Longeveron's therapeutic product candidates.

Portfolio Pulse from Benzinga Newsdesk

January 29, 2024 | 1:02 pm